Riggioni, CarmenComberiati, PasqualeGiovannini, MattiaAgache, IoanaAkdis, MübeccelAlves-Correia, MagnaAntó, Josep M.Arcolaci, AlessandraAzkur, Ahmet KursatAzkur, DilekBeken, BurcinBoccabella, CristinaBousquet, JeanBreiteneder, HeimoCarvalho, DanielaDe las Vecillas, LeticiaDiamant, ZuzanaEguiluz-Gracia, IbonEiwegger, ThomasEyerich, StefanieFokkens, WytskeGao, Ya-dongHannachi, FarahJohnston, Sebastian L.Jutel, MarekKaravelia, AspasiaKlimek, LudgerMoya, BeatrizNadeau, Kari C.O'Hehir, RobynO'Mahony, LiamPfaar, OliverSanak, MarekSchwarze, JürgenSokolowska, MilenaTorres, María J.Van de Veen, WillemVan Zelm, Menno C.Wang, De YunZhang, LuoJiménez-Saiz, RodrigoAkdis, Cezmi A.2021-06-152021-06-1520200105-4538http://hdl.handle.net/10641/2322In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID-19). This disease, caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), has developed into a pandemic. To date, it has resulted in similar to 9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID-19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence-based medical advice on SARS-CoV-2 and COVID-19. Although the majority of the patients show a very mild, self-limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID-19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a "cytokine storm" leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID-19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID-19-related topics should be based on more coordinated high-quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS-CoV-2, COVID-19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID-19 and allergic disease.engAtribución-NoComercial-SinDerivadas 3.0 Españahttp://creativecommons.org/licenses/by-nc-nd/3.0/es/AllergyCoronavirus disease 2019COVID-19SARS-CoV-2Severe acute respiratory syndrome-related coronavirus 2journal articleopen access10.1111/all.14449